Medidata Acorn AI Supports EUSA Pharma’s Relaunch of SYLVANT® in the US Market

Medidata Acorn AI’s commercial data management technology helps identify  previously untreated and undiagnosed patients 

New York, NY – March 24, 2021 – Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that its  Acorn AI commercial data management technology was used by oncology biopharmaceutical company EUSA Pharma for the U.S. commercial relaunch of SYLVANT (siltuximab).

Medidata Acorn AI Commercial Data Solutions provides commercial pharmaceutical organizations with the data management and insights needed to maximize brand success. EUSA Pharma is using Medidata’s STRATA® end-to-end commercial data management platform and LUMEN InsightsTM to empower its sales and marketing teams with data-driven insights to identify previously untreated patients, remove barriers to treatment, and improve patient adherence.  

“We consider Medidata Acorn AI technology to be the cornerstone of our digital commercial analytics platform. This helped us maintain a lean infrastructure, and more importantly better understand our business,” said Mickey Baker, Head of U.S. Market Access & Operations at EUSA Pharma. “Medidata Acorn AI Commercial Data Solutions worked as a trusted extension of our team, not only from a technological viewpoint, but for their data expertise as well.” 

The commercial data model developed through the Medidata Acorn AI Commercial Data Solutions team is designed to scale with new indications and products, which will complement EUSA Pharma’s planned commercial strategy and operations. The commercial data model will enable people at all levels of EUSA Pharma to access a single source of truth and create readable, intuitive reports about SYLVANT’s commercial performance. 

“Our Commercial Data Solutions team completed a fully remote implementation of STRATA and LUMEN to support EUSA Pharma's SYLVANT relaunch,” said Frank Lane, Medidata Acorn AI, vice president, Customer Success and Delivery Excellence. “It speaks to our team's technical expertise and ability to be nimble and adjust during the COVID-19 pandemic, as we continue to help pharmaceutical companies execute on their launch strategies.”

From identifying and retaining patients, discovering biomarkers, accelerating diagnosis, and delivering insights into complex patient populations, Medidata is advancing oncology and rare disease trials by expediting outcomes and improving experiences. These diseases are often poorly understood with limited treatment options and data for physicians to select the most appropriate therapy for patients. For example, Medidata published research, in collaboration with the Castleman Disease Collaborative Network, which used Rave Omics to identify potential biomarkers for early response to treatment. 

Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE  platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. 

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit https://www.3ds.com